VivoSeq
Other

MRD

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

MRD is an early-stage landscape with 0 programs across 2 companies. The most active players are GammaDelta Therapeutics Limited, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

GammaDelta Therapeutics Limited

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Recruiting2 · 33%
Completed2 · 33%
Terminated1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

MRD-positive AML Clinical Study
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT07131059·120 enrolled
Mosunetuzumab for CLL MRD Clearance
Recruiting·—·Phase 1/2·NCT07052695·40 enrolled
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05434689·80 enrolled
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT01216384·73 enrolled
FLYSYN in MRD Positive AML
Completed·SSynimmune GmbH·Phase 1/2·NCT02789254·31 enrolled
Study of GDX012 in Patients With MRD Positive AML
Terminated·GGammaDelta Therapeutics Limited·Phase 1·NCT05001451·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)